Multitarget Drug Discovery for Alzheimer's Disease: Triazinones as BACE-1 and GSK-3β Inhibitors
Federica Prati, Dr. Angela De Simone, Dr. Paola Bisignano, Dr. Andrea Armirotti, Dr. Maria Summa, Dr. Daniela Pizzirani, Dr. Rita Scarpelli, Dr. Daniel I. Perez, Prof. Dr. Vincenza Andrisano, Dr. Ana Perez-Castillo, Prof. Dr. Barbara Monti, Francesca Massenzio, Dr. Letizia Polito, Prof. Dr. Marco Racchi, Dr. Angelo D. Favia, Dr. Giovanni Bottegoni, Prof. Dr. Ana Martinez, Prof. Dr. Maria Laura Bolognesi and Prof. Dr. Andrea Cavalli
Article first published online: 11 DEC 2014 | DOI: 10.1002/anie.201410456
Two for one: Alzheimer's disease is a complex multifactorial syndrome which calls for the development of multitarget drugs. Accordingly, triazinones are reported here as the first molecule class which is able to simultaneously modulate BACE-1 and GSK-3β activity. Such dual-target inhibitors, by acting against two crucial enzymes in the neurotoxic pathways, might represent a breakthrough in the quest for disease-modifying drugs.